NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma announced positive Phase 3 BROADWAY trial results for obicetrapib, showing a 33% LDL-C reduction vs. placebo at day 84 (p<0.0001), a 21% reduction in major adverse cardiovascular events at one year, and good tolerability. The company plans to discuss regulatory filings in 2025.

NewAmsterdam Pharma announced positive Phase 3 BROADWAY trial results for obicetrapib, showing a 33% LDL-C reduction vs. placebo at day 84 (p<0.0001) and a 21% reduction in major adverse cardiovascular events at one year. Obicetrapib was well-tolerated with safety comparable to placebo.

NewAmsterdam Pharma announced positive Phase 3 BROADWAY trial results for obicetrapib, showing a 33% reduction in LDL-C levels and a 21% reduction in MACE. The drug's safety profile was comparable to placebo. The company plans to discuss regulatory filings in 2025 and present detailed data at a medical conference.

NewAmsterdam Pharma announced positive Phase 3 BROADWAY study results for obicetrapib in treating ASCVD and HeFH, achieving a 33% LDL-C reduction. The drug was well-tolerated, leading to a >50% stock increase pre-market.

Hunters at risk for heart attack/stroke due to physical exertion and colder temperatures. Positive results for sotatercept in pulmonary arterial hypertension. Fixed-dose combination of obicetrapib and ezetimibe nearly halved LDL cholesterol in statin-resistant patients. TAVR tradeoffs in permanent pacemaker rates and patient-prosthesis mismatch. Better outcomes with Sapien 3 Ultra Resilia TAVR valve. Michigan cardiologist sues for whistleblower retaliation. Machine learning algorithm RF-SLAM predicts mortality and heart failure hospitalization. Dapagliflozin reduces new-onset diabetes in cardiovascular/kidney disease patients. SGLT2 inhibitors improve outcomes in hypertrophic cardiomyopathy with diabetes. GLP-1 receptor agonists show kidney and cardiovascular benefits. Cilostazol reduces in-stent restenosis risk. Bartonella quintana infection risk in solid-organ transplant recipients. Donor-specific antibodies and allograft dysfunction linked to poor prognosis in heart transplant recipients. Regenerative capacity of human cardiomyocytes minimal in heart failure unless on left ventricle support device therapy.

NewAmsterdam Pharma announces promising Phase 3 TANDEM trial results, showing a fixed-dose combination of obicetrapib and ezetimibe significantly reduces LDL-C levels by 50% and over 70% of patients achieved LDL-C levels below 55 mg/dL, well-tolerated and supporting global regulatory filings.

NewAmsterdam Pharma announced positive Phase 3 TANDEM trial results, showing obicetrapib and ezetimibe fixed-dose combo significantly reduced LDL-C by 48.6% vs. placebo at day 84, supporting global regulatory filings.

Phase III BROOKLYN trial results presented at AHA 2024 show obicetrapib significantly reduces LDL cholesterol in HeFH patients, with 34% achieving >50% reduction. Obicetrapib also lowers Lp(a) by 54.3% and raises HDL cholesterol, with no serious adverse events reported.

The Phase III BROOKLYN trial presented at AHA 2024 showed obicetrapib significantly reduced LDL cholesterol by 41.5% at 365 days, with 34% of patients achieving >50% reduction. Obicetrapib also lowered Lp(a) by 54.3%, addressing unmet need in dyslipidemia treatment.

NewAmsterdam Pharma announced additional Phase 3 BROOKLYN trial results for obicetrapib, showing significant LDL-C, Lp(a), and LDL particle reductions in HeFH patients on maximally tolerated lipid-lowering therapy, with safety comparable to placebo.